BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:agenT-797 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of agenT-797\, from ClinicalTrials.gov estim
 ates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07615010-3287@assetmemo.bio
DTSTAMP:20261121T004528Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:agenT-797: Phase 2 readout est. (NCT07615010)
DESCRIPTION:agenT-797\, phase 2.\nStudy: A Clinical Trial to Evaluate agenT
 -797 Plus Standard of Care in Participants With Severe Pneumonia With Mode
 rate to Severe Acute Hypoxemic Respiratory Failure\nEstimated primary comp
 letion: June 2027. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ag
 ent-797#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT07615010
URL:https://assetmemo.bio/drug/agent-797#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06251973-3287@assetmemo.bio
DTSTAMP:20261121T004528Z
DTSTART;VALUE=DATE:20270801
DTEND;VALUE=DATE:20270802
SUMMARY:agenT-797: Phase 2 readout est. (NCT06251973)
DESCRIPTION:agenT-797\, phase 2\, Gastric Cancer.\nStudy: A Study of agenT-
 797 in Combination With Botensilimab\, Balstilimab\, Ramucirumab\, and Pac
 litaxel for People With Esophageal\, Gastric\, or Gastro-esophageal Juncti
 on Cancer\nEstimated primary completion: 1 August 2027. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/agent-797#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT06251973
URL:https://assetmemo.bio/drug/agent-797#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07550088-3287@assetmemo.bio
DTSTAMP:20261121T004528Z
DTSTART;VALUE=DATE:20280930
DTEND;VALUE=DATE:20281001
SUMMARY:agenT-797: Phase 2 readout est. (NCT07550088)
DESCRIPTION:agenT-797\, phase 2.\nStudy: BAL/BOT/agenT-797 in pMMR CRC With
  Liver Metastases\nEstimated primary completion: September 2028. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/agent-797#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT07550088
URL:https://assetmemo.bio/drug/agent-797#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07758218-3287@assetmemo.bio
DTSTAMP:20261121T004528Z
DTSTART;VALUE=DATE:20291031
DTEND;VALUE=DATE:20291101
SUMMARY:agenT-797: Phase 1 readout est. (NCT07758218)
DESCRIPTION:agenT-797\, phase 1.\nStudy: Allogeneic iNKT Cell Therapy (agen
 T-797) After SCT\nEstimated primary completion: October 2029. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/agent-797#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT07758218
URL:https://assetmemo.bio/drug/agent-797#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
